Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Evox To Raise Cash In 2018 For Novel Exosome Platform

Executive Summary

Emerging Company Profile: Evox Therapeutics – a privately held, Oxford-based biotechnology company developing a new class of biotherapeutics called exosomes – is using its technology to improve the delivery of validated therapies, particularly targeting central nervous system and neuromuscular conditions.

You may also be interested in...

Novo's €2.6bn Ablynx Bid Opens The Door For Better Offers

Gilead, Amgen and AbbVie are names that could join the fray should a bidding war start for Nanobody drug developer Ablynx, which has rebuffed two takeover offers from Novo Nordisk.

Effective Integration Is The Key To BD Success For Ipsen

At the 2023 BIO-Europe conference, In Vivo sat down with Ipsen’s EVP and chief business officer, Philippe Lopes-Fernandes, to discuss the company’s business development strategy and future goals.

Scrip 100: By The Numbers

Pfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts